Safety and Efficacy of XT-150 for Treatment of Neuropathic Pain
A Double Blind, Placebo Controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Neuropathic Pain
Sponsor: Xalud Therapeutics, Inc.
Terminated
Failure to enroll a sufficient number of patients.
A PHASE1 clinical study on Neuropathic Pain, this trial is terminated or withdrawn. The trial is conducted by Xalud Therapeutics, Inc. and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Nov 2021 — Jun 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Xalud Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .